Intersect ENT Inc (XENT) Is An Opportunity To Get In On An Under Reaction

Yesterday, Intersect ENT Inc (NASDAQ:XENT) announced that a phase III pivotal trial for its lead candidate met its endpoints, and that the company is set to put forward an authorization...

Keep Reading →